4月21日，沪深两融数据显示，昭衍新药上周累计获融资净买入额1264.42万元，居两市第232位，上周融资买入额1.42亿元，偿还额1.30亿元。
昭衍新药所属概念板块包括：医疗服务、北京板块、专精特新、宁组合、标准普尔、富时罗素、沪股通、上证380、融资融券、预亏预减、股权激励、AH股、创新药、CRO、生物疫苗。
资金流方面，昭衍新药近5日主力资金流出542.53万元，区间跌幅0.28%；近10日主力资金流出2.83亿元，区间跌幅6.73%。
天眼查商业履历信息显示，北京昭衍新药研究中心股份有限公司，成立于1998年，位于北京市，是一家以从事研究和试验发展为主的企业。企业注册资本53567.8676万人民币，实缴资本4560.33万人民币。公司法定代表人为冯宇霞。
通过天眼查大数据分析，北京昭衍新药研究中心股份有限公司共对外投资了20家企业，参与招投标项目42次，知识产权方面有商标信息67条，专利信息55条，此外企业还拥有行政许可43个。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.